Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJEKQM)

Drug Name

EP-128504 Drug Info

Synonyms

MX-116839; MX-126374; MX-126911; MX-128504; MX-74420; MX-77356; IGF modulator (cancer), Maxim; IGF-2 receptor modulators (cancer); IGF-2 receptor modulators (cancer), EpiCept; IGF-2 receptor modulators (cancer), Maxim; Insulin-like growth factor modulator (cancer), Maxim

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Cross-matching ID

TTD Drug ID: DMJEKQM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting CI Man-6-P receptor (IGF2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Juvidex	DMZKYNO	Sarcoidosis	4B20.5	Phase 2	[3]
PXS-25	DMVQJOS	Fibrosis	GA14-GC01	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CI Man-6-P receptor (IGF2R)	TTPNE41	MPRI_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017941)
2	The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. Mol Cancer Ther. 2005 May;4(5):761-71.
3	Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125.
4	Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93.